We are proud to announce that Indigo Diabetes NV has been selected as one of just 65 startups to join the prestigious 2025 MedTech Innovator Accelerator Cohort.
Chosen from a pool of nearly 1,500 global applicants, this places us among the top 4% of emerging medtech innovators worldwide.

This recognition is a powerful endorsement of our mission to bring transformative diabetes technology to life. We are honoured to be part of a program that supports breakthrough medical technologies and helps scale innovations that improve patient care.

We are deeply grateful to the mentors, investors, and reviewers who share our vision and continue to support our journey. A heartfelt thank you to MedTech Innovator for this incredible opportunity, we’re excited to take this next step in advancing healthcare together.

We are proud to announce that Indigo has been recognized as a ‘Key Innovator‘ by the European Commission’s Innovation Radar for its groundbreaking work on the Multi-Metabolite Sensor, developed within the MuSiC4Diabetes project. This recognition underscores Indigo’s commitment to advancing diabetes technology and improving patient outcomes.

Indigo’s multi-metabolite sensor has been categorized as ‘Tech Ready’ by the Innovation Radar, signifying its strong potential for real-world application. Additionally, it has been rated with ‘High’ market creation potential, highlighting its ability to drive significant advancements in diabetes management.

The inclusion of Indigo in the Innovation Radar highlights the impact of our dedication to translating cutting-edge research into practical healthcare solutions.
We are excited about the future and look forward to leveraging this opportunity to bring our innovation to market.

Indigo Diabetes NV is proud to announce the successful completion of the SHINE Study, a six-month feasibility trial of our implantable continuous multi-metabolite monitor — designed to measure glucose, ketone, and lactate concentrations in real time.

By eliminating the need for external wearables and delivering continuous, multi-metric insights, this innovation positions Indigo as a frontrunner in the $100B+ global diabetes care market.

Unlike traditional glucose-only monitors, Indigo’s technology captures additional key metabolic markers:

• Ketones offer early detection of ketosis and diabetic ketoacidosis (DKA), helping users and clinicians intervene before complications arise.
• Lactate serves as an indicator of metabolic stress, exercise intensity, and potential hypoxia—offering broader insights into overall metabolic health.

Key findings from the SHINE Study include:

• A strong safety profile with no device-related serious adverse events
• Robust technical feasibility for long-term, continuous spectral monitoring
• Positive patient-reported usability in real-world, at-home settings

Conducted under MDR 2017/745 and ISO 14155:2020, the study confirmed that our technology can reliably collect spectral data over extended periods. Feedback from participants underscored the benefits of a discreet, low-burden alternative to traditional wearable sensors.

This milestone marks a significant step forward in the evolution of next-generation diabetes and metabolic care. With strong early performance data, unique multi-analyte capabilities, and a clear path to regulatory advancement, Indigo is shaping the future of diabetes management.

Indigo  is pleased to announce the successful completion of its annual EN ISO 13485:2016 surveillance audit, conducted by TÜV SÜD, reaffirming its certification for the design and development of biomarker sensing devices and services.

This certification emphasizes the Indigo’s commitment to maintaining a quality management system that meets or exceeds the rigorous standards set for the international medical device industry.

The company remains dedicated to delivering the highest quality products and services, ensuring compliance and driving continuous improvement across its processes. 

Indigo has been granted U.S. Patent No. 11,992,310 for its personal health monitoring system. This revolutionary technology is designed to enhance continuous health monitoring by using a minimally invasive insertable sensor to track critical parameters like glucose and ketones, providing real-time insights for patients managing conditions such as diabetes.

Indigo’s patented system is a leap forward in user-centered health care, as it adapts data collection rates based on patient stability, optimizing power use and ensuring long-term functionality. With this innovation, Indigo aims to improve patient outcomes through seamless, around-the-clock monitoring while also delivering valuable data for large-scale health analysis.

We’re absolutely thrilled to share some fantastic news with you all! Our CEO, Danaë Delbeke, has been recognized as one of the 100 Most Prominent Women in Belgian Media!
This prestigious acknowledgment highlights her remarkable leadership, dedication, and undeniable impact in the industry, inspiring us all along the way.

Congratulations, Danaë, on this well-deserved recognition!

 Dive into the full list of influential women here: https://www.finn.agency/finn-female-leaders-ranking-the-100-most-prominent-women-in-belgian-media-2023/